Cancer discovery news
Our researchers are making the discoveries that defeat cancer. Read the latest findings from our world-leading research.
Visit our main news hub to read about news on new funding, our fundraising activities and much more. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
One week radiotherapy course shown to be safe and effective in the long term for early stage breast cancer
A one-week course of post-surgery radiotherapy is just as safe and effective as the traditional three-week course for people with early-stage breast cancer, according to long-term results from a ground-breaking study, led by The Institute of Cancer Research, London
Early scan could help predict breast cancer treatment response
Research led by The Institute of Cancer Research, London and King’s College London suggests that an early scan taken after one cycle of chemotherapy could help to predict how well a patient’s cancer will respond to treatment.
Men can be safely treated with two radiotherapy sessions for localised prostate cancer with no increase in side effects in comparison to five sessions
Men with localised prostate cancer could benefit from a shorter course of radiotherapy, after new research data shows that just two higher-dose treatments are as safe as a standard five-session regimen, with no increase in side effects.
Childhood leukaemia and germs: research reveals the critical importance of timing
New research has endorsed a long standing idea explaining why acute lymphoblastic leukaemia (ALL) – the most common cancer in children – appears abruptly in early life, often in otherwise healthy individuals, with no obvious environmental trigger.
Newly discovered role for cancer-linked protein exposes vulnerability in tumour cells
Scientists have uncovered a previously hidden role for a protein frequently mutated in cancer, showing that it helps maintain the stability of the genome at some of its most vulnerable sites.
Local anaesthetic shows promise in blocking childhood cancer spread, study finds
A drug best known for numbing the skin before minor medical procedures may hold unexpected promise in tackling one of the most aggressive childhood cancers.
Seeing the immune system in action: new imaging study sheds light on cancer immunotherapy
Experts have demonstrated that an innovative, non-invasive imaging technique can be harnessed to monitor oncolytic virotherapy, a rapidly advancing field of cancer treatment.
Excess weight is the strongest clue to the rise in cancer rates in under 50s
Being overweight or obese is an important cause of rising cancer rates among younger adults in England, according to a major new study by researchers from The Institute of Cancer Research, London
New AI tool to assist pathologists in complicated lung cancer analyses
Researchers have developed an artificial intelligence (AI) tool that helps doctors more accurately measure a key marker used to decide which lung cancer patients might benefit from certain treatments.
-16-9.jpg?sfvrsn=b9495114_2 "Glioblastoma cells (Dr Chris Jones/the ICR) 16:9")
ICR plays key role in groundbreaking new brain cancer trials
Scientists from The Institute of Cancer Research (ICR), London, are taking part in a groundbreaking new set of brain cancer clinical trials designed to improve survival and quality of life for people with glioblastoma.
-growing-in-single-files-along-collagen-fibres-(red)_renee-flaherty.jpg?sfvrsn=b3bf3bc8_3 "Invasive lobular breast cells (yellow) growing in single files along collagen fibres (red)_Renee Flaherty")
Scientists identify a potential new treatment option for lobular breast cancer
A drug currently being tested in clinical trials for a rare blood cancer could also be used to treat lobular breast cancer, according to a study published in the journal Cancer Research.
Scientists develop new way to determine which patients will respond best to bowel cancer treatment
Scientists have developed an AI-powered method that could determine which patients with advanced bowel cancer are most likely to respond to a targeted drug used on the NHS – potentially sparing thousands of patients from treatments that won’t work for them.